Apontis Pharma AG

XETRA APPH.DE

Apontis Pharma AG Shareholders' Equity for the year ending December 31, 2023: USD 33.40 M

Apontis Pharma AG Shareholders' Equity is USD 33.40 M for the year ending December 31, 2023, a -24.89% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Apontis Pharma AG Shareholders' Equity for the year ending December 31, 2022 was USD 44.47 M, a -4.04% change year over year.
  • Apontis Pharma AG Shareholders' Equity for the year ending December 31, 2021 was USD 46.35 M, a 997.07% change year over year.
  • Apontis Pharma AG Shareholders' Equity for the year ending December 31, 2020 was USD 4.22 M, a -18.89% change year over year.
  • Apontis Pharma AG Shareholders' Equity for the year ending December 31, 2019 was USD 5.21 M.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
SV Wall Street
XETRA: APPH.DE

Apontis Pharma AG

CEO Mr. Bruno Wohlschlegel
IPO Date May 11, 2021
Location Germany
Headquarters Alfred-Nobel-Str. 10
Employees 177
Sector Healthcare
Industries
Pharmaceuticals Drugstores & Retail Pharmacies
Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

StockViz Staff

February 6, 2025

Any question? Send us an email